Sermorelin Profile

Sermorelin is a 29-amino-acid synthetic GHRH (growth hormone releasing hormone) analogue that stimulates the pituitary to release its own GH in natural pulses. Half-life is 11-12 minutes, so it must be dosed nightly at 200-500 mcg subcutaneously before bed. Approved by the FDA in 1990 for pediatric GH deficiency under the brand Geref. Modern use is adult anti-aging, sleep improvement, and body composition over 3-6 month cycles. The cleanest, oldest GH peptide – safer than CJC-1295, weaker than the modern stacks.

What is Sermorelin?

Sermorelin (also called GRF 1-29 or growth hormone releasing factor) is the first 29 amino acids of the natural 44-amino-acid GHRH molecule. Researchers discovered that this truncated fragment retains full biological activity at the GHRH receptor, making it a clean and economical synthetic substitute for the full hormone. Pediatric endocrinology pioneered its use in the 1980s and the FDA approved it in 1990 under the brand name Geref for children with growth hormone deficiency.

How does Sermorelin work?

Sermorelin binds the GHRH receptor on pituitary somatotroph cells, triggering them to release stored growth hormone in physiological pulses. Three mechanism details matter:

• Pulse preservation: Sermorelin elevates GH only when the pituitary is naturally responsive – it does not flatline natural rhythm
• Negative feedback intact: somatostatin still suppresses GH when levels rise – no overshoot
• Pituitary stimulation: chronic use can actually upregulate somatotroph cells, improving baseline GH output

This is fundamentally different from synthetic HGH (which replaces GH directly) or CJC-1295 with DAC (which produces constant elevated GH bleed). Sermorelin works within natural feedback loops rather than overriding them.

What dose should you use?

Standard protocol:

• Adult anti-aging: 200-300 mcg subcutaneously, nightly before bed
• Body composition: 300-500 mcg subcutaneously, nightly
• Maximum recommended: 500 mcg single dose, 1000 mcg/day total

Dose timing matters: 30-60 minutes before sleep amplifies the natural overnight GH pulse. Fasted state (3+ hours after last meal) maximizes response because food, especially carbs, blunts GH release by 50-70%.

How long is a Sermorelin cycle?

Standard cycle:

• 12-24 weeks on, 4-8 weeks off
• Effects build cumulatively over the first 4-8 weeks
• Plateau around week 10-12
• Bloodwork at week 8 confirms IGF-1 elevation

Unlike most GH peptides, Sermorelin can be run for longer cycles because the receptor desensitization is much slower. Some users run 6-month cycles with a 1-month break, while others prefer shorter 12-week cycles with longer breaks. The 4-week minimum off period restores GHRH receptor sensitivity.

What results should you expect?

Realistic outcomes over a 12-24 week cycle at 300 mcg/night:

• Deeper sleep, more vivid dreams
• Faster recovery between training sessions
• Slight body composition improvement (1-3 lb lean gain, modest fat loss)
• Improved skin quality and tendon resilience
• Modest energy and mood improvements
• Possible mild joint stiffness improvement

Sermorelin is a slow, clean tool. It does not produce the dramatic body composition changes seen with HGH or CJC+Ipamorelin stacks. The trade-off is that gains hold better long-term because the GH axis stays functional throughout.

How does Sermorelin compare to CJC-1295?

Both are GHRH analogues but with key differences:

• Sermorelin: 29 amino acids, half-life 11-12 minutes, natural pulse pattern
• CJC-1295 (no DAC): similar half-life, slightly more stable receptor binding
• CJC-1295 with DAC: half-life 7-8 days, constant GH elevation (GH bleed)

Sermorelin is the classic, well-studied option with the cleanest safety profile. CJC-1295 without DAC is functionally similar but slightly more potent per dose. CJC-1295 with DAC produces stronger effects at the cost of disrupting natural pulsatility. Our CJC+Ipa profile covers the stack approach.

What are the side effects?

At standard 200-500 mcg doses:

• Injection-site flush (universal, fades in 5-10 minutes)
• Mild headache during first week
• Vivid or unusual dreams
• Slight water retention
• Mild numbness or tingling in extremities

No HPTA suppression. No appetite explosion. No cortisol spike. The safety profile is the cleanest of any GH peptide commonly used. Long-term users in clinical settings have run Sermorelin for 5+ years without significant adverse events.

What bloodwork should you run?

Before and at week 8 of the cycle:

• IGF-1 (the gold-standard GH proxy)
• Fasting glucose and insulin
• HbA1c
• Full lipid panel
• Thyroid panel (TSH, free T4) – GH increases T4 conversion

Target IGF-1 elevation of 30-60% above baseline. If IGF-1 spikes above 350 ng/mL in healthy adults, reduce dose. Sermorelin rarely produces excessive IGF-1 elevation because the natural feedback loops stay intact.

How do you reconstitute Sermorelin?

Standard reconstitution for the 5 mg vial:

• 5 mg + 2 mL bacteriostatic water = 2500 mcg/mL
• 200 mcg = 0.08 mL = 8 units on 100-unit insulin syringe
• 300 mcg = 0.12 mL = 12 units
• 500 mcg = 0.2 mL = 20 units

Reconstituted Sermorelin stays stable refrigerated for 28-30 days. Lyophilized powder stable 18-24 months at room temperature in sealed containers. Subcutaneous injection into abdominal fat or thigh – rotate sites weekly. Our reconstitution guide covers the math.

Is Sermorelin legal in Canada?

Pharmaceutical Sermorelin (Geref) is no longer manufactured but its generic ingredients are sold through Canadian compounding pharmacies with a prescription. Research peptide Sermorelin operates in a separate regulatory category – sold for research purposes only, not Health Canada approved for human consumption. WADA prohibits Sermorelin in athletic competition; detection windows on extended urine tests run 5-7 days post-dose. Full Health Canada drug regulations.

Sources

• Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging, 2006.
• Frohman LA, Jansson JO. Growth hormone-releasing hormone. Endocr Rev, 1986.
• Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev, 2018.
• FDA Geref prescribing information, 1990 approval.